A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate (CR rate) between the experimental cohort and the historical control cohort (NCT04833504).

Trial Details

NCT ID

NCT07788118

Phase

PHASE1 / PHASE2

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

7×19-THEMIS CAR-T cells

Locations (sample)

Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

Voluntarily participate in this study and sign the informed consent form.
Age range: 18 - 75 years old. Gender is not restricted.
Histologically confirmed large B-cell lymphoma, including: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL)…
CD19-positive (as determined by immunohistochemistry or flow cytometry; based on the most recent tumor biopsy results).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →